Our group and Shi's group have proved inhibition of KDM1A can convert tumors from “cold” to “hot” via regulating the tumor immunogenicity [7, 13] and suppose KDM1A as a target to enhance the efficacy of immunotherapy on poor immunogenic cancers. The gene discussed is KDM1A; the disease is cancer.